Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Gets Septin9 Test Reimbursement in France

NEW YORK (GenomeWeb News) – Epigenomics today said that it a French supplementary insurance provider will provide coverage for the firm's Septin9 test for early detection of colorectal cancer.

The Berlin, Germany-based molecular diagnostics firm said that Mutuelle d’Assurance du Corps de Santé Français (MACSF) will reimburse €50 ($68.80) for the test.

MACSF offers additional health insurance to around 800,000 policy holders, according to Epigenomics. It is the second insurer in France to provide reimbursement for Septin9 testing, following a decision last year by Swiss Life to offer the test as part of its preventive health program.

Epigenomics' flagship product is its Epi proColon test, which is based on the Septin9 biomarker. The test is marketed in Europe, and the firm is awaiting a US Food and Drug Administration decision for marketing in the US.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.